Analysts Recommend ‘Hold’ for DENTSPLY SIRONA
July 11, 2023
☀️Trending News
Analysts at four brokerages recently recommended a “Hold” rating for DENTSPLY SIRONA ($NASDAQ:XRAY) Inc., a leading manufacturer and distributor of dental and oral health products. Analysts have concluded that, at its current levels, DENTSPLY SIRONA Inc. stock is fairly valued and thus the “Hold” recommendation is warranted. The company’s financials have improved over the last couple of quarters and its cash flow has been on a positive trend. Furthermore, analysts anticipate that the company’s new product launches and improved pricing strategies will help drive future growth.
Overall, the average recommendation of “Hold” from the four brokerages covering DENTSPLY SIRONA Inc. appears to be well earned. Investors who are looking to add this stock to their portfolio should consider the current market conditions and the company’s future prospects before making any decisions.
Market Price
On Monday, analysts recommended a ‘Hold’ for DENTSPLY SIRONA Inc. stock. The stock opened at $38.9 and closed at $39.6, up by 1.9% from the previous closing price of 38.8. This increase was driven by the general market sentiment, as well as investors and traders betting on the future of the company.
The company produces dental and medical products that are in high demand globally, which has provided a steady source of revenue. Overall, analysts believe this stock is a safe bet for investors looking to hold for the long-term. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Dentsply Sirona. More…
| Total Revenues | Net Income | Net Margin |
| 3.93k | -1.04k | 4.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Dentsply Sirona. More…
| Operations | Investing | Financing |
| 403 | -132 | -302 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Dentsply Sirona. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 7.67k | 4.04k | 17.14 |
Key Ratios Snapshot
Some of the financial key ratios for Dentsply Sirona are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -0.2% | -10.5% | -28.1% |
| FCF Margin | ROE | ROA |
| 6.6% | -18.5% | -9.0% |
Analysis
At GoodWhale, we provide comprehensive financial analysis on DENTSPLY SIRONA to help you make informed investment decisions. Our Risk Rating for DENTSPLY SIRONA is high, meaning that the company has a higher than average risk in terms of financial and business aspects. We have detected 2 risk warnings in DENTSPLY SIRONA’s income sheet and balance sheet. If you want to learn more about these warnings, sign up with us and check out our analysis. With GoodWhale, you can rest assured that your investments are made wisely and backed by comprehensive financial insights. More…
Peers
In the competitive world of dental equipment manufacturers, Dentsply Sirona Inc. has held its own against some tough competitors. Edwards Lifesciences Corp, Escalon Medical Corp, and Medistim ASA are all companies that produce dental equipment and supplies that compete with Dentsply Sirona Inc.
– Edwards Lifesciences Corp ($NYSE:EW)
Edwards Lifesciences Corp is a medical technology company that specializes in products and technologies for the treatment of cardiovascular diseases. The company’s market capitalization is $45.45 billion as of 2022, and its return on equity is 18.9%. Edwards Lifesciences is headquartered in Irvine, California, and has operations in more than 75 countries worldwide.
– Escalon Medical Corp ($OTCPK:ESMC)
Escalon Medical Corp is a medical device company that manufactures and markets products for the ophthalmology, optometry, and veterinary markets worldwide. It has a market cap of 800.11k as of 2022 and a return on equity of 1.57%. The company’s products include ophthalmic surgical instruments, intraocular lenses, contact lenses, and disposables.
– Medistim ASA ($BER:MD1)
Medistim ASA is a Norwegian medical device company that develops, manufactures, and markets products for use in cardiac and vascular surgery. The company has a market capitalization of 455.95 million as of 2022 and a return on equity of 24.86%. Medistim’s products are used in a variety of procedures, including coronary artery bypass graft surgery, valve replacement surgery, and endovascular surgery. The company’s products are sold in over 50 countries worldwide.
Summary
Investing in DENTSPLY SIRONA Inc. can be a viable option for investors, as the company has earned an average recommendation of “Hold” from the four brokerages that are currently covering it. Analysts suggest that investors should hold their current positions in the stock, as the company is likely to remain range bound for the near future. Furthermore, DENTSPLY SIRONA Inc. appears to have a good balance sheet with no significant financial issues or debt levels. The company’s expected earnings and cash flow growth should also provide investors with a reasonable return on their investments.
However, investors should keep an eye on any changes in the company’s near-term outlook or any potential risks that may affect its long-term prospects.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
